Zika virus (ZIKV) is a mosquito-borne flavivirus distributed all over Africa， South America and Asia. The infection with the virus may cause acute febrile sickness that clinically resembles dengue fever， yet there is no vaccine， no satisfactory treatment， and no means of evaluating the risk of the disease or prognosis in the infected people. In the present study， the efficacy of the host's immune response in reducing the risk of infectious diseases was taken into account to carry out immuno-informatics driven epitope screening strategy of vaccine candidates against ZIKV. In this study， HLA distribution analysis was done to ensure the coverage of the vast majority of the population. Systematic screen... More
Zika virus (ZIKV) is a mosquito-borne flavivirus distributed all over Africa， South America and Asia. The infection with the virus may cause acute febrile sickness that clinically resembles dengue fever， yet there is no vaccine， no satisfactory treatment， and no means of evaluating the risk of the disease or prognosis in the infected people. In the present study， the efficacy of the host's immune response in reducing the risk of infectious diseases was taken into account to carry out immuno-informatics driven epitope screening strategy of vaccine candidates against ZIKV. In this study， HLA distribution analysis was done to ensure the coverage of the vast majority of the population. Systematic screening of effective dominant immunogens was done with the help of Immune Epitope & ABCPred databases. The outcomes suggested that the predicted epitopes may be protective immunogens with highly conserved sequences and bear potential to induce both protective neutralizing antibodies， T & B cell responses. A total of 25 CD4+ and 16 CD8+ peptides were screened for T-cell mediated immunity. The predicted epitope "TGLDFSDLYYLTMNNKHWLV" was selected as a highly immunogenic epitope for humoral immunity. These peptides were further screened as non-toxic， immunogenic and non-mutated residues of envelop viral protein. The predicted epitope could work as suitable candidate(s) for peptide based vaccine development. Further， experimental validation of these epitopes is warranted to ensure the potential of B- and T-cells stimulation for their efficient use as vaccine candidates， and as diagnostic agents against ZIKV.
